At Adiso, we develop novel medicines to treat inflammatory diseases, prioritizing patient safety and efficacy. Our pipeline includes small molecules and single strain live biotherapeutic products (SS-LBPs) with innovative mechanisms of action. Currently, ADS024 (SS-LBP) is in Phase 1b studies for re...See more
Headquarters:
United States of America
Company Type:
SME
Company size:
11-50 Employees
Year Founded:
2022 (4 years)
Address:
CONCORD, MASSACHUSETTS 01742, US
LOW
spending power
